Broad-Spectrum Vaccines: Challenges and Opportunities (A Systematic Review)

Though advances in technologies have created an arena for multiple vaccinology platforms, the world population is still facing health challenges from the deadliest pathogens with a high mutation rate and their tremendous ability of immune evasion. Presently, there is a constant exigence to shift the vaccine development efforts from traditional vaccines to broad-spectrum vaccines for the effective prevention of contagious diseases.

Using several databases, a comprehensive systematic review of the literature pertinent to this article's discussion was carried out.

The present review article aims to provide a comprehensive understanding of the key characteristics and benefits of broad-spectrum vaccines over conventional vaccines. Further, it unveils the diverse range of broad-spectrum vaccines that have been developed so far, in addition to those that are currently under pre-clinical and clinical studies. Along with the illustration of the obstacles and possibilities concerned with their safety profile and viability of development, it also examines their potential for further research.

The development of broad-spectrum vaccines benefits greatly from the combination of several immunisation strategies. The scope and effectiveness of broadspectrum vaccinations have been shown to be greatly increased by combining various vaccination tactics, such as using multiple immunisation techniques, multivalent antigens, or heterologous boosters.

The development and practical validation of broad-spectrum vaccines have been impeded thus far by biological complexity (rapid pathogen evolution, immune imprinting, host variability), logistical limitations, and regulatory frameworks intended for strain-specific products, leaving the majority of candidates at preclinical stages. To turn promising ideas into gradual, population-level protection, policy support, and focused research improving evaluation techniques, altering regulatory pathways, and advancing mRNA, multiepitope, and T-cell approaches are required.